This Week in Cardiology

Latest Episodes:

Jan 13 2023 This Week in Cardiology Jan 13, 2023

Show notes

FOURIER authors' response, a possible practice-changing paper in electrophysiology, and the ATLAS and CAPLA trials are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit: https://www.medscape.com/twic

I. FOURIER Authors Respond

Recount of FOURIER Data Finds Higher Mortality With Evolocumab; Trialists Push Back https://www.medscape.com/viewarticle/986634

Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data https://bmjopen.bmj.com/content/12/12/e060172
Letter to the Editor RE: "Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data". BMJ Open https://bmjopen.bmj.com/content/12/12/e060172.responses#letter-to-the-editor-re-restoring-mortality-data-in-the-fourier-cardiovascular-outcomes-trial-of-evolocumab-in-patients-with-cardiovascular-disease-a-reanalysis-based-on-regulatory-data-bmj-open-2022123060172
Risk of selection bias assessment in the NINDS rt-PA stroke study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202115/
Methodological survey of missing outcome data in an alteplase for ischemic stroke meta-analysis https://doi.org/10.1111/ane.13656

II. A Potential Practice-Changing Paper in Cardiac Pacing

Novel 'Cure' May Avert Lead Extraction in CIED Pocket Infections https://www.medscape.com/viewarticle/986762

Regional Antibiotic Delivery for Implanted Cardiovascular Electronic Device Infections https://doi.org/10.1016/j.jacc.2022.10.022
Treatment of Localized Implantable Cardiac Device Pocket Infections https://doi.org/10.1016/j.jacc.2022.11.018

III. ATLAS Trial

Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations https://doi.org/10.7326/M22-1566
Subcutaneous or Transvenous Defibrillator Therapy https://www.nejm.org/doi/full/10.1056/NEJMoa1915932
Subcutaneous or Transvenous Defibrillator Therapy https://www.nejm.org/doi/10.1056/NEJMc2034917

IV. CAPLA Published

CAPLA Shows Limits of Further Ablation Post PVI in Persistent AF https://www.medscape.com/viewarticle/986901

Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation https://jamanetwork.com/journals/jama/fullarticle/2800186
Catheter Ablation for Persistent Atrial Fibrillation https://jamanetwork.com/journals/jama/fullarticle/2800200

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact

news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Jan 6 2023 This Week in Cardiology Jan 06, 2023

Show notes

Damar Hamlin, obesity and semaglutide, Open Data and PCSK9 inhibitors, and TAVI vs SAVR trials are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Damar Hamlin

Five Thoughts on the Damar Hamlin Collapse

https://www.medscape.com/viewarticle/986550

II. Semaglutide and Obesity in Adolescents

FDA Approves Wegovy (Semaglutide) for Obesity in Teens 12 and Up

https://www.medscape.com/viewarticle/986403

• Once-Weekly Semaglutide in Adolescents with Obesity https://www.nejm.org/doi/full/10.1056/NEJMoa2208601

III. Open Data and PCSK9 inhibitors

Evolocumab Added to Statins Cuts CV Events in FOURIER Trial

https://www.medscape.com/viewarticle/877348

• Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data

https://bmjopen.bmj.com/content/12/12/e060172

• Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

https://www.nejm.org/doi/full/10.1056/nejmoa1615664

• PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction https://pubmed.ncbi.nlm.nih.gov/34252181/

• Bendary Tweet https://twitter.com/DrBendary/status/1609849852979986432?s=20&t=FDDhGIofS_HQ4jxf8aHwBA

IV. Open Data and TAVI vs SAVR Trials

Risk of Bias in Randomized Clinical Trials Comparing Transcatheter and Surgical Aortic Valve Replacement https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799937

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dec 23, 2022, This Week in Cardiology Podcast Dec 23, 2022

Show notes

The top ten stories of the year plus a few honorary mentions. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic

I Annual Wrap Ups on Medscape

- Mandrola's Top 10 Cardiology Stories of 2022 https://www.medscape.com/viewarticle/985607

- 2022 in Review Through a Cardiology Lens https://www.medscape.com/viewarticle/984505

- Top Cardiology Trials of 2022 https://www.medscape.com/viewarticle/985647

II REVIVED BCIS2

- Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction https://www.nejm.org/doi/full/10.1056/nejmoa2206606

- PCI Fails in Stable Disease Again: REVIVED-BCIS https://www.medscape.com/viewarticle/979862

- PCI Fails to Beat OMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 https://www.medscape.com/viewarticle/979853

III GUIDE HF

- Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial https://doi.org/10.1016/S0140-6736(21)01754-2

- CardioMEMS Remote HF Monitoring: Resist the Spin and FOMO https://www.medscape.com/viewarticle/970278

- GUIDE-HF: CardioMEMS-Guided Meds Fall Short in Mild to Moderate Heart Failure https://www.medscape.com/viewarticle/957390

IV DECAAF II

- Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation The DECAAF II Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2793452

- DECAAF II: AF, Fibrosis Ablation Technique Falls Short, but Signs of Hope https://www.medscape.com/viewarticle/957469

V DANCAVAS

- Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681

- DANCAVAS Misses Primary Endpoint but Hints at Benefit from Comprehensive CV Screening https://www.medscape.com/viewarticle/979854

- Judicious CVD Screening May Work in Men: DANCAVAS https://www.medscape.com/viewarticle/980153

- DANCAVAS: Might Cardiovascular Screening Extend Men's Lives? https://www.medscape.com/viewarticle/979632

VI SODIUM HF

- Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial https://doi.org/10.1016/S0140-6736(22)00369-5

- Low-Sodium Diet Did Not Cut Clinical Events in Heart Failure Trial https://www.medscape.com/viewarticle/971482

- Sodium Restriction in Heart Failure: Another Dogma Felled by Randomization https://www.medscape.com/viewarticle/971697

- SODIUM-HF Simplifies Message to Patients on Diet https://www.medscape.com/viewarticle/971547

VII STRONG-HF

- Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial https://doi.org/10.1016/S0140-6736(22)02076-1

- Rapidly, Fully Optimize HF Meds After Hospital Discharge: STRONG-HF https://www.medscape.com/viewarticle/983870

- STRONG HF: More Beats Less After Discharge for Heart Failure https://www.medscape.com/viewarticle/983698

VIII Health Insurance Access

- Health Care Access and Management of Cardiovascular Risk Factors Among Working-Age Adults With Low Income by State Medicaid Expansion Status https://doi.org/10.1001/jamacardio.2022.1282

- Medicaid Expansion: Good First Step, but No Panacea for CV Care https://www.medscape.com/viewarticle/975141

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dec 16, 2022 This Week in Cardiology Podcast Dec 16, 2022

Show notes

BP control over the long term, omecamtiv mecarbil, incentives and Goodhart's law, and open science are the topics John Mandrola, MD, covers in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic

I. Long-Term BP Control

- Final SPRINT Data Confirm Lower BP Is Better https://www.medscape.com/viewarticle/951572

- Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control https://jamanetwork.com/journals/jamacardiology/fullarticle/2797064

- Let's Not SPRINT to Judgment About New Blood Pressure Goals https://www.acpjournals.org/doi/full/10.7326/M15-3123

- Should We SPRINT Toward New Blood Pressure Goals or Let the Dust Settle? https://doi.org/10.1016/j.amjmed.2016.04.022

II. Omecamtiv Mecarbil

- FDA Panel Votes No on Omecamtiv Mecarbil for Heart Failure https://www.medscape.com/viewarticle/985593

- Omecamtiv Mecarbil Fails to Improve Exercise Capacity in HFrEF https://www.medscape.com/viewarticle/978355

- Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa2025797

- Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction https://jamanetwork.com/journals/jama/fullarticle/2794362

- Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial https://doi.org/10.1093/eurheartj/ehac293

III. Measuring Quality of Care

- MIPS Quality Scores Don't Reflect Quality of Care: Study https://www.medscape.com/viewarticle/985396

- Association Between Individual Primary Care Physician Merit-based Incentive Payment System Score and Measures of Process and Patient Outcomes https://jamanetwork.com/journals/jama/article-abstract/2799153

- Pay for Performance When Slogans Overtake Science in Health Policy https://jamanetwork.com/journals/jama/fullarticle/2799177

- Goodhart's law https://en.wikipedia.org/wiki/Goodhart%27s_law

IV. Open Science

- Radial Artery Outlasts SVG as Second CABG Conduit, Cuts 5-Year Clinical Risk https://www.medscape.com/viewarticle/896122

- Many Analysts, One Data Set: Making Transparent How Variations in Analytic Choices Affect Results https://doi.org/10.1177/2515245917747646

- Radial artery versus saphenous vein versus right internal thoracic artery for coronary artery bypass grafting https://academic.oup.com/ejcts/article/62/1/ezac345/6604735?login=false

- Do all roads lead to Rome? Critical reassessment of the individual patient meta-analysis on bypass grafts by Gaudino et al. https://doi.org/10.1093/ejcts/ezac564

- Editorial: Radial artery versus saphenous vein versus right internal thoracic artery for coronary artery bypass grafting: Different conduits or different trials? https://doi.org/10.1093/ejcts/ezac562

Features

- Mandrola's Top 10 Cardiology Stories of 2022 https://www.medscape.com/viewarticle/985607

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dec 9, 2022 This Week in Cardiology Podcast Dec 09, 2022

Show notes

Nudges, statins, AI, less-is-more in the ICU, myocarditis, exercise as medicine, and December in the hospital are the topics John Mandrola, MD, covers in this week's podcast.

This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Nudges and Statin Prescribing

EHR Alerts to Both Doc and Patient May Boost Statin Prescribing

https://www.medscape.com/viewarticle/984944

Effect of Nudges to Clinicians, Patients, or Both to Increase Statin Prescribing

https://jamanetwork.com/journals/jamacardiology/article-abstract/2798971

Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia

https://jamanetwork.com/journals/jama/fullarticle/2719307

Lack of Efficacy of a Salience Nudge for Substituting Selection of Lower-Calorie for Higher-Calorie Milk in the Work Place https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488787/

II. AI and Chest X-Ray

Single Chest X-Ray Could Predict 10-Year CVD Risk

https://www.medscape.com/viewarticle/984910

III. BOX Trial

Shorter Fever Prevention Duration Effective After Cardiac Arrest

https://www.medscape.com/viewarticle/984852

Duration of Device-Based Fever Prevention after Cardiac Arrest

https://www.nejm.org/doi/10.1056/NEJMoa2212528

Oxygen Targets in Comatose Survivors of Cardiac Arrest

https://www.nejm.org/doi/full/10.1056/NEJMoa2208686

Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest

https://www.nejm.org/doi/full/10.1056/NEJMoa2208687

Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure

https://www.nejm.org/doi/full/10.1056/NEJMoa2032510

IV. Myocarditis

Mortality Higher in Myocarditis After Virus Than After COVID Vax

https://www.medscape.com/viewarticle/985045

Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination

https://link.springer.com/article/10.1007/s00392-022-02129-5#Tab2

Myopericarditis After COVID-19 mRNA Vaccination Among Adolescents and Young Adults

https://jamanetwork.com/journals/jamapediatrics/fullarticle/2798866

Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis

https://www.jacc.org/doi/full/10.1016/j.jacc.2022.09.049

V. Exercise as Medicine

Just 8 Minutes of Exercise a Day Is All You Need

https://www.medscape.com/viewarticle/984684

Vigorous physical activity, incident heart disease, and cancer: how little is enough? https://doi.org/10.1093/eurheartj/ehac572

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

John M Mandrola, MD

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dec 2, 2022 This Week in Cardiology Podcast Dec 02, 2022

Show notes

SGLT2 inhibitors, publishing choices, second and third order effects of interventions, decision support, and patient selection for preventive procedures are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic

I. EMPA Kidney

- EMPA-Kidney Seals SGLT2 Inhibitors as 'Foundational' for CKD https://www.medscape.com/viewarticle/984439

- EMPA-Kidney Moves the Needle for SGLT2 Inhibitors in Kidney Disease https://www.medscape.com/viewarticle/983521

- Empagliflozin in Patients with Chronic Kidney Disease https://www.nejm.org/doi/pdf/10.1056/NEJMoa2204233

- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy https://www.nejm.org/doi/10.1056/NEJMoa1811744

- Dapagliflozin in Patients with Chronic Kidney Disease https://www.nejm.org/doi/full/10.1056/NEJMoa2024816

- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials https://doi.org/10.1016/S0140-6736(22)02074-8

II. Publishing Choices

- Motorcycle Rallies Linked to Spike in Organ Transplants https://www.medscape.com/viewarticle/984623

- Organ Donation and Transplants During Major US Motorcycle Rallies https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2798550

III. Second and Third Order Effects

- Heart Disease Deaths Spiked During COVID After 10-Year Decline https://www.medscape.com/viewarticle/984605

IV. Decision Support

- Patient App Aids Decisions on Anticoagulants: ENHANCE-AF https://www.medscape.com/viewarticle/984253

- A Randomized Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision‐Making Pathway https://www.ahajournals.org/doi/10.1161/JAHA.122.028562

V. Percutaneous Left Atrial Appendage Closure

- Consider Life Expectancy When Referring for LAA Closure? https://www.medscape.com/viewarticle/981117

- Transcatheter Left Atrial Appendage Occlusion: A Multi-Center Real Life Experience https://www.mdpi.com/2077-0383/11/23/6944

- Incidence and Predictors of Early Death in Patients Undergoing Percutaneous Left Atrial Appendage Closure https://www.jacc.org/doi/full/10.1016/j.jacep.2022.06.012

- Indications for Left Atrial Appendage Occlusion in the United States and Associated In-Hospital Outcomes: Results From the NCDR LAAO Registry https://www.ahajournals.org/doi/full/10.1161/CIRCOUTCOMES.121.008418

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Nov 18, 2022, This Week in Cardiology Nov 18, 2022

Show notes

AHA 2022, Part 2: IRONMAN, ECMO-CS, CTS-AMI, and PROGRESSIVE AF are the trials John Mandrola, MD, reviews in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Pushback on PROMINENT

Zimerman Thread: https://twitter.com/AndreZimerman/status/1593019800036708353

II. IRONMAN

IRONMAN Galvanizes Case for IV Iron Repletion in Heart Failure

https://www.medscape.com/viewarticle/984030

Is Iron Replacement in Heart Failure Worth the Trouble?

https://www.medscape.com/viewarticle/983622

- Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial https://doi.org/10.1016/S0140-6736(22)02083-9

III. ECMO-CS

Avoid Routine Early ECMO in Severe Cardiogenic Shock: ECMO-CS

https://www.medscape.com/viewarticle/983618

- Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062949

- Venoarterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock and Cardiac Arrest https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.118.004905

IV. CTS-AMI

Chinese Herbal Medicine May Offer Benefits in STEMI: CTS-AMI

https://www.medscape.com/viewarticle/983619

V. PROGRESSIVE AF

First-Line AF Ablation Cuts Risk of Progression vs Drug Therapy

https://www.medscape.com/viewarticle/983882

Role of Ablation Type and Risk Factors in Paroxysmal AF: PROGRESSIVE-AF Interview https://www.medscape.com/viewarticle/983474

- Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation

https://www.nejm.org/doi/full/10.1056/nejmoa2029980

- Progression of Atrial Fibrillation after Cryoablation or Drug Therapy

https://www.nejm.org/doi/10.1056/NEJMoa2212540

- Natural History of Subclinical Atrial Fibrillation Detected by Implanted Loop Recorders

https://pubmed.ncbi.nlm.nih.gov/31779791/

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact

news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Nov 11, 2022 This Week in Cardiology Podcast Nov 11, 2022

Show notes

AHA 2022 Part 1: ISCHEMIA-EXTEND, STRONG-HF, chlorthalidone vs HCTZ, experts vs practitioners; torsemide vs furosemide; and TG lowering are discussed by John Mandrola, MD, in this week's podcast.

This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic

I. AHA Meta-comments

II. ISCHEMIA-Extended

- ISCHEMIA-EXTEND: Conservative Stable CAD Management Holds Up https://www.medscape.com/viewarticle/983657

- Survival After Invasive or Conservative Management of Stable Coronary Disease https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062714

III. STRONG-HF

- Rapidly, Fully Optimize HF Meds After Hospital Discharge: STRONG-HF https://www.medscape.com/viewarticle/983870

- STRONG HF: More Beats Less After Discharge for Heart Failure https://www.medscape.com/viewarticle/983698

IV. DCP

- Diuretic Agents Equal to Prevent CV Events in Hypertension: DCP https://www.medscape.com/viewarticle/983608

- HCTZ vs Chlorthalidone -- A Win for Practicing Doctors and Science https://www.medscape.com/viewarticle/983614

V. TRANSFORM HF

- No Survival Advantage for Either Torsemide or Furosemide in HF: TRANSFORM-HF https://www.medscape.com/viewarticle/983611

VI. PROMINENT

- Triglyceride Lowering Fails to Show CV Benefit in Large Fibrate Trial https://www.medscape.com/viewarticle/983610

- Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk https://www.nejm.org/doi/full/10.1056/NEJMoa2210645

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Nov 4, 2022 This Week in Cardiology Podcast Nov 04, 2022

Show notes

AF conversion in the ED, HRT, a shining example of evidence-based medicine and less-is-more, multimorbidity, and what's coming at AHA are the topics John Mandrola, MD, covers in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic

I. AF Conversion

- IV Potassium and Magnesium an Acute Treatment for AF? https://www.medscape.com/viewarticle/983137

- Association of Intravenous Potassium and Magnesium Administration With Spontaneous Conversion of Atrial Fibrillation and Atrial Flutter in the Emergency Department https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797474

II. HRT

- USPSTF Doesn't Change Postmenopausal Hormone Recommendations https://www.medscape.com/viewarticle/983349

- Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women https://doi.org/10.7326/0003-4819-117-12-1016

- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal WomenPrincipal Results From the Women's Health Initiative Randomized Controlled Trial https://jamanetwork.com/journals/jama/fullarticle/195120

- Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal PersonsUS Preventive Services Task Force Recommendation Statement https://jamanetwork.com/journals/jama/fullarticle/2797867

- Menopausal Hormone Therapy for Prevention of Chronic Conditions https://jamanetwork.com/journals/jama/fullarticle/2797897

III. BP Targets After Stroke Intervention

- Intensive BP Lowering Harmful in Acute Ischemic Stroke: ENCHANTED2/MT https://www.medscape.com/viewarticle/983176

- Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial https://doi.org/10.1016/S0140-6736(22)01882-7

IV. Multimorbidity

- ACC Issues Guidance on Integrating ASCVD and Multimorbidity Care https://www.medscape.com/viewarticle/983123

- 2022 ACC Expert Consensus Decision Pathway for Integrating Atherosclerotic Cardiovascular Disease and Multimorbidity Treatment: A Framework for Pragmatic, Patient-Centered Care: A Report of the American College of Cardiology Solution Set Oversight Committee https://www.jacc.org/doi/10.1016/j.jacc.2022.08.754

V. AHA Preview

- AHA 2022 to Recapture In-Person Vibe but Preserve Global Reach https://www.medscape.com/viewarticle/983315

- Mandrola's Top 5 Picks From AHA 2022 Previewed https://www.medscape.com/viewarticle/983237

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Oct 28 2022 This Week in Cardiology Oct 28, 2022

Show notes

ERASE AF follow-up, recreational drugs and AF, etripamil, misuse of science, and diabetes as a cardiovascular risk factor are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Follow-up on ERASE AF

II. Recreational Drugs

Four Commonly Abused Drugs Linked With Atrial Fibrillation

https://www.medscape.com/viewarticle/983052

III. Etripamil

RAPID: Positive Data for Etripamil Nasal Spray in Paroxysmal SVT

https://www.medscape.com/viewarticle/982787

- Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia https://investors.milestonepharma.com/news-releases/news-release-details/milestone-pharmaceuticals-announces-positive-results-phase-3

IV. Misuse of Science

When Bad Actors Hijack Good Research

https://www.medscape.com/viewarticle/982936

- Level and Prevalence of Spin in Published Cardiovascular Randomized Clinical Trial Reports With Statistically Nonsignificant Primary Outcomes: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/31050775/

V. Diabetes as a Risk Factor

Diabetes Becoming Less Potent Risk Factor for CVD Events

https://www.medscape.com/viewarticle/982801

- Trends in the Association Between Diabetes and Cardiovascular Events, 1994-2019 https://jamanetwork.com/journals/jama/fullarticle/2797494

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact

news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected